Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0032463 (
polycythemia vera
)
3,374
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Because of recent developments in the study of vitamin B12-binding proteins, the levels of the three serum binders were compared in serum and plasma samples from subjects with various disorders. The results allow the following conclusions: (1) As previously reported, transcobalamin (TC) III and to a lesser extent
TC I
are artifactually elevated in serum. The appear to be released in vitro during the clotting process, presumably from granulocytes. (2) Blood cells of patients with
polycythemia vera
release exceedingly large amounts of
TC I
and TC III in vitro. (3) The above findings support, but do not prove, at least a partial granulocytic source of
TC I
. Nevertheless, factors other than granulocytes influence
TC I
levels, as disorders characterized by increased
TC I
(most prominently chronic myelogenous leukemia but also several cases of cancer) manifest relatively little cellular release of
TC I
in vitro. (4) Despite the serum artifact, the serum abnormalities described in various conditions were seen in plasma also, even though the actual values of themselves were lower in plasma. The chief exception was TC III, which was elevated in plasma only in
polycythemia vera
(and in a few cases of leukocytosis). (5) EDTA-NaF anticoagulant is not suitable, as it causes plasma dilution, thus explaining previous reports of TC II level differences between serum and plasma. EDTA is therefore a preferable anticoagulant for vitamin B12-binding protein studies, although it too may not be ideal.
...
PMID:Vitamin B12-binding proteins in serum and plasma in various disorders. Effect of anticoagulants. 41 9
The unsaturated vitamin B12 binding capacity of whole serum (UBBC) and of the three transcobalamins (TC) has been studied in patients with various haematological diseases including myeloproliferative disorders (MPD) and acute leukaemia. The binding capacity of
TC I
and TC III was increased in MPD;
TC I
being particularly high in chronic granulocytic leukaemia (CGL) and TC III especially raised in
polycythaemia rubra vera
(
PRV
) and in infectious leucocytosis. The binding capacity of both
TC I
and TC III correlated with blood neutrophil count and the ratio TC III/
TC I
was low in CGL and increased in
PRV
. TC II was increased in acute myelogenous leukaemia, during remission and blast cell crisis of CGL and in refractory anaemia with excess of myeloblasts but not in acute lymphoblastic leukaemia (ALL). TC II correlated inversely with blood neutrophil count. There is an inverse ratio between TC II and
TC I
at least in myelogenous leukaemia. These abnormalities are discussed in relation to granulocyte kinetics. TC III and
TC I
reflect probably the total body granulocyte pool and share some biochemical and immunological properties supporting the view that they have a common origin in the more mature stages of the granulocyte cell line while TC II probably originates partly in more primitive granulocytes.
...
PMID:The three transcobalamins in myeloproliferative disorders and acute leukaemia. 105 79
